Michael Dellinger

Dr. Michael Dellinger is an Associate Professor in the Departments of Surgery and Molecular Biology at UT Southwestern Medical Center. He serves as Director of Research for the Lymphatic Malformation Institute and collaborates with organizations like the LGDA. His research focuses on identifying novel treatments for complex lymphatic anomalies, particularly in disorders such as Gorham-Stout disease and lymphatic malformations. He completed his Ph.D. at the University of Arizona and postdoctoral training at UT Southwestern.

His research interests encompass lymphatic vessel development, genetic and molecular mechanisms underlying lymphatic disorders, and the intersection of lymphatic biology with cancer and bone pathologies. Key themes include KRAS/MAPK signaling pathways, lymphatic-vascular interactions, and targeted therapies using agents like trametinib.

Publications highlight advancements in single-cell lymphatic analysis, novel drug delivery systems for lymph nodes, and mechanistic studies of lymphatic dysfunction in bone diseases. His work bridges basic science and translational medicine, with implications for rare disease treatment and cancer therapy.

Dr. Dellinger’s contributions include developing mouse models of lymphatic anomalies and collaborating on projects funded by initiatives like the Chan-Zuckerberg Initiative. His lab remains a leader in elucidating lymphatic system biology and its clinical applications.